{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:09:47Z","timestamp":1788174587881,"version":"build-2803163510"},"reference-count":211,"publisher":"Informa UK Limited","issue":"3","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2026,2,11]]},"DOI":"10.1080\/14656566.2026.2644384","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T10:52:10Z","timestamp":1773139930000},"page":"193-210","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacologic progress in higher-risk MDS: an uphill battle"],"prefix":"10.1080","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4388-4825","authenticated-orcid":false,"given":"Alain","family":"Mina","sequence":"first","affiliation":[{"name":"Yale University","place":["New Haven, CT, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[{"name":"Yale University","place":["New Haven, CT, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2017.12.002"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.09.001"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025271"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-785915"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200008"},{"key":"e_1_3_4_10_1","unstructured":"[cited 2025 Nov 12]. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ivosidenib-myelodysplastic-syndromes"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2015.06.004"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.275"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.0806"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1307361"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2784"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2013.01.001"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023075"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.08.014"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-200519"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23607"},{"issue":"1","key":"e_1_3_4_25_1","first-page":"21","article-title":"Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes","volume":"7","author":"Silverman LR","year":"1993","unstructured":"Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7(1):21\u201329. PubMed PMID: 7683352.","journal-title":"Leukemia"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.117"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"e_1_3_4_28_1","unstructured":"[cited 2025 Oct 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/208216s007lbl.pdf"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.33"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.283"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14305"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0081-8"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11543"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.5.956"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21792"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.9245"},{"key":"e_1_3_4_37_1","unstructured":"[cited 2025 Oct 31]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021790s006lbl.pdf"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2238897"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207241257313"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241238979"},{"key":"e_1_3_4_41_1","unstructured":"[cited 2025 Oct 31st]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-oral-combination-decitabine-and-cedazuridine-myelodysplastic-syndromes"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004143"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00338-1"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.211"},{"key":"#cr-split#-e_1_3_4_45_1.1","unstructured":"US Food and Drug Administration. FDA approves ivosidenib for relapsed or refractory acute myeloid leukemia. [accessed 5 January 2023"},{"key":"#cr-split#-e_1_3_4_45_1.2","unstructured":"cited 2025 Nov 5]. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ivosidenib-relapsed-or-refractory-acute-myeloid-leukemia"},{"key":"#cr-split#-e_1_3_4_46_1.1","unstructured":"US Food and Drug Administration. FDA approves ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia. [accessed 5 January 2023"},{"key":"#cr-split#-e_1_3_4_46_1.2","unstructured":"cited 2025 Nov 5]. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ivosidenib-combination-azacitidine-newly-diagnosed-acute-myeloid-leukemia"},{"key":"e_1_3_4_47_1","unstructured":"US Food and Drug Administration. FDA approves ivosidenib as first-line treatment for AML with IDH1 mutation. [cited 2023 Jan 5]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ivosidenib-first-line-treatment-aml-idh1-mutation"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146932"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012302"},{"key":"#cr-split#-e_1_3_4_50_1.1","unstructured":"US Food and Drug Administration. FDA approves ivosidenib for myelodysplastic syndromes. [accessed Jan 4 2024"},{"key":"#cr-split#-e_1_3_4_50_1.2","unstructured":"cited 2025 Nov 5]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ivosidenib-myelodysplastic-syndromes"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061664"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1915986"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-02108-8"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/mog2.22"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-014-1656-6"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0443-x"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2019.08.008"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19123952"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2022.09.002"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-10-1247"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.009217"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-732123"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2510"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29812"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.05.021"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02073-x"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30949"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30533"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.7556"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2016-0526"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02036-2"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-021873"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.3102"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13832"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0343"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature07884"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-805895"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01125-4"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007334"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-518886"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129392"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.218453"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.7783"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02341"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02342"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000421"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16162780"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03004"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.016"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00561-4"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2019.1589374"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2024.09.006"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3763"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100709"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005240"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119424"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601202"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2034155"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.03.007"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2014.93"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.3390\/life11060465"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.167.2.452"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-844654"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.637.637"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.806243"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-173162"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0224-6"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146039"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(22)01420-3"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00333-2"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-1237"},{"key":"e_1_3_4_114_1","unstructured":"Abstract: S180 Title: PRIMARY RESULTS OF THE PHASE III STIMULUS-MDS2 STUDY OF SABATOLIMAB + AZACITIDINE VS PLACEBO + AZACITIDINE AS FRONTLINE THERAPY FOR PATIENTS WITH HIGHER-RISK MDS OR CMML-2 Abstract Type: Oral Presentation. Madrid Spain: EHA Congress; 2024."},{"key":"e_1_3_4_115_1","unstructured":"[cited 2025 Oct 15]. Available from: https:\/\/pharmaphorum.com\/news\/novartis-calls-time-tim3-drug-sabatolimab-mds"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14011"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.355"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0645-z"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-206672"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005487"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207251347344"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1182\/hem.V18.4.2021410"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2022000351"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7017"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01794"},{"key":"e_1_3_4_126_1","unstructured":"[cited 2025 Oct 15]. Available from: https:\/\/www.gilead.com\/news\/news-details\/2023\/gilead-to-discontinue-phase-3-enhance-study-of-magrolimab-plus-azacitidine-in-higher-risk-mds"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-024-03761-8"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.09.004"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-152692"},{"key":"e_1_3_4_130_1","first-page":"8","article-title":"NKG2D ligands as therapeutic targets","volume":"13","author":"Spear P","year":"2013","unstructured":"Spear P, Wu MR, Sentman ML, et al. NKG2D ligands as therapeutic targets. Cancer Immun. 2013;13:8. PubMed PMID: 23833565.","journal-title":"Cancer Immun"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00378-7"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0399"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.192807"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008806"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016229"},{"key":"e_1_3_4_136_1","unstructured":"[cited 2025 Oct 28]. Available from: https:\/\/www.fda.gov\/drugs\/fda-approves-venetoclax-combination-aml-adults"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025464"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26771"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7054"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)02083-X"},{"key":"e_1_3_4_142_1","volume-title":"ASH Annual Meeting","author":"Garcia-Manero G","year":"2025","unstructured":"Garcia-Manero G, Platzbecker U, Fenaux P, et al. Subgroup analyses from the randomized phase 3 VERONA study of venetoclax with azacitidine versus placebo with azacitidine in patients with treatment-na\u00efve intermediate- and higher-risk myelodysplastic syndromes. ASH Annual Meeting; Orlando, CA; 2025 Dec 6\u20139. Abstract 235."},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-024-01264-7"},{"key":"e_1_3_4_144_1","unstructured":"[cited 2025 Dec 13]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-olutasidenib-relapsed-or-refractory-acute-myeloid-leukemia-susceptible-idh1-mutation"},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009411"},{"key":"e_1_3_4_146_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016718"},{"key":"e_1_3_4_147_1","unstructured":"[cited 2025 Nov 5]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-granted-regular-approval-enasidenib-treatment-relapsed-or-refractory-aml"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30284-4"},{"key":"e_1_3_4_149_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008378"},{"key":"e_1_3_4_150_1","unstructured":"[cited 2025 Dec 29]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mds.pdf"},{"key":"e_1_3_4_151_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00038-8"},{"key":"e_1_3_4_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30029-8"},{"key":"e_1_3_4_153_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100008"},{"key":"e_1_3_4_154_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.136"},{"key":"e_1_3_4_155_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01319-y"},{"key":"e_1_3_4_156_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000693"},{"key":"e_1_3_4_157_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000843408.31385.3f"},{"key":"e_1_3_4_158_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-019-0314-5"},{"key":"e_1_3_4_159_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200323859"},{"issue":"16","key":"e_1_3_4_160_1","first-page":"6513","article-title":"Bexmarilimab plus azacitidine in relapsed\/refractory higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML): updated results from the BEXMAB phase 1\/2 trial","volume":"43","author":"Py\u00f6r\u00e4l\u00e4 M","year":"2025","unstructured":"Py\u00f6r\u00e4l\u00e4 M, Kuusanm\u00e4ki H, Kontro M, et al. Bexmarilimab plus azacitidine in relapsed\/refractory higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML): updated results from the BEXMAB phase 1\/2 trial. J Clin Oncol. 2025;43(16 Su ppl):6513.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_161_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(25)00103-6"},{"key":"e_1_3_4_162_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-236"},{"key":"e_1_3_4_163_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205371"},{"key":"e_1_3_4_164_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.6505"},{"key":"e_1_3_4_165_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-3417"},{"key":"e_1_3_4_166_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023005"},{"key":"e_1_3_4_167_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4821"},{"key":"e_1_3_4_168_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.8073"},{"key":"e_1_3_4_169_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.88"},{"key":"e_1_3_4_170_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02175"},{"key":"e_1_3_4_171_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4503"},{"key":"e_1_3_4_172_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.7349"},{"key":"e_1_3_4_173_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.7091"},{"key":"e_1_3_4_174_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.08.007"},{"key":"e_1_3_4_175_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012385"},{"key":"e_1_3_4_176_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.10.012"},{"key":"e_1_3_4_177_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024013853"},{"key":"e_1_3_4_178_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215943"},{"key":"e_1_3_4_179_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015173"},{"key":"e_1_3_4_180_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00184"},{"key":"e_1_3_4_181_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002544"},{"key":"e_1_3_4_182_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.234"},{"key":"e_1_3_4_183_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30580-1"},{"key":"e_1_3_4_184_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012120"},{"key":"e_1_3_4_185_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00181"},{"key":"e_1_3_4_186_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001482"},{"key":"e_1_3_4_187_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.8135"},{"key":"e_1_3_4_188_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-57295-5"},{"key":"e_1_3_4_189_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17152469"},{"key":"e_1_3_4_190_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.312"},{"key":"e_1_3_4_191_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01696-4"},{"key":"e_1_3_4_192_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029727"},{"key":"e_1_3_4_193_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023166"},{"key":"e_1_3_4_194_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0275399"},{"key":"e_1_3_4_195_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2021.112837"},{"key":"e_1_3_4_196_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5479013"},{"key":"e_1_3_4_197_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30903"},{"key":"e_1_3_4_198_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014865"},{"key":"e_1_3_4_199_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023717"},{"key":"e_1_3_4_200_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/62.7.722"},{"key":"e_1_3_4_201_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0666-7"},{"key":"e_1_3_4_202_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018604"},{"key":"e_1_3_4_203_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4149"},{"key":"e_1_3_4_204_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2024-0322-RA"},{"key":"e_1_3_4_205_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00251-5"},{"key":"e_1_3_4_206_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01724-9"},{"key":"e_1_3_4_207_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.873"},{"key":"e_1_3_4_208_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0719"},{"key":"e_1_3_4_209_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.04.027"},{"key":"e_1_3_4_210_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1649313"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2026.2644384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:22:26Z","timestamp":1774516946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2026.2644384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":211,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,11]]}},"alternative-id":["10.1080\/14656566.2026.2644384"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2026.2644384","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-01-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}